BioSpace News Archive

The gadgets utilized in the medical care settings for the reprocessing techniques of the endoscopes are called endoscope reprocessing gadgets.

Cerevel Therapeutics Holdings, Inc. announced the pricing of its previously announced underwritten public offering of 7,250,000 shares of its common stock at a public offering price of $35.00 per share, or approximately $253.8 million of shares of its common stock.

InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company for the treatment of cancer and autoimmune diseases, announced today that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) accepted a supplemental New Drug Application (sNDA) for Bruton’s tyrosine kinase (BTK) inhibitor orelabrutinib for the treatment of patients with relapsed or refractory Marginal Zone Lymphoma.

Alvotech announced that its Board of Directors has approved a plan to move its share listing from the First North Growth Market to the Nasdaq Main Market in Iceland.

Chemomab Therapeutics, Ltd. announced the addition of Ilan Vaknin, PhD, MBA, as Vice President of Research & Development and Christina Crater, MD, as Vice President of Clinical Development.

An in-depth article authored by Florida Cancer Specialists & Research Institute, LLC pharmacy experts published in the American Journal of Managed Care® issues a call to action for the development of improved metrics to help lower costs and better assess the performance of pharmacies that dispense oral oncolytic medications.

Umbra Applied Technologies Group, Inc. announced that its subsidiary, The Dreaming Company, LLC, is re-branding and expanding its highly lauded Hygieia Skin care product suite as “Hygieia Ageless”.

ROKIT Healthcare, a company specializing in bio-healthcare, announced it will provide a hyper-personalized medical platform that uses 3D bioprinting and AI technology built on Google Cloud, to innovate the treatment of osteoarthritis and diabetes feet.

Guardant Health Receives FDA Approval for Guardant360 ® CDx as Companion Diagnostic for Daiichi Sankyo and AstraZeneca’s ENHERTU ® for Treatment of NSCLC Patients With Activating HER2 Mutations.

Xenetic Biosciences, Inc. today reported its financial results for the second quarter of 2022 and provided a business update.